|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||
  Internal Medicine JournalVolume 35 Issue 6, Pages 348 - 356 Published Online: 13 May 2005 Journal compilation © 2009 Royal Australasian College of Physicians The Official Journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP)
Abstract | References | Full Text: HTML, PDF (Size: 946K) | Related Articles | Citation Tracking  Review Update on the use of stem cells for cardiac disease Funding: This research is supported in part by grants from the St Vincent's Clinic Foundation, the RT Hall Estate, the Macquarie Foundation, the National Health and Medical Research Council and the Australian Stem Cell Centre. Potential conflicts of interest: None Copyright 2005 Royal Australasian College of Physicians KEYWORDS stem cell • progenitor • cardiac • regeneration ABSTRACTAbstract Major advances have recently been made in our understanding of stem cell biology, and in the application of stem cells to treat cardiac disease. Resident cardiac stem cells have now been described and the long-accepted paradigm of the adult mammalian heart as an organ without regenerative capacity has been questioned. Various stem-cell-based approaches for ameliorating cardiac disease have been shown to be beneficial in animal models and are now being trialled in humans, with several phase I clinical studies already completed. Although these clinical studies lacked adequate placebo controls, they have consistently shown promising results. If confirmed by larger phase II/III trials, it is possible that within a few years a powerful new therapeutic option may be available for the burgeoning number of patients suffering from myocardial ischaemia and/or other cardiac disorders. (Intern Med J 2005; 35: 348–356) Received 5 November 2004; accepted 28 February 2005. | 
|
